BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 14985451)

  • 21. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
    Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
    Liu X; Gao Y; Shen J; Yang W; Choy E; Mankin H; Hornicek FJ; Duan Z
    Mol Cancer Ther; 2016 Jul; 15(7):1691-701. PubMed ID: 27207777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SOX2 expression associates with stem cell state in human ovarian carcinoma.
    Bareiss PM; Paczulla A; Wang H; Schairer R; Wiehr S; Kohlhofer U; Rothfuss OC; Fischer A; Perner S; Staebler A; Wallwiener D; Fend F; Fehm T; Pichler B; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
    Cancer Res; 2013 Sep; 73(17):5544-55. PubMed ID: 23867475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
    Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.
    Rosanò L; Spinella F; Di Castro V; Nicotra MR; Dedhar S; de Herreros AG; Natali PG; Bagnato A
    Cancer Res; 2005 Dec; 65(24):11649-57. PubMed ID: 16357176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
    Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
    Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
    Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
    [No Abstract]   [Full Text] [Related]  

  • 33. Expressions of cytochrome P450, UDP-glucuronosyltranferase, and transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice.
    Sugawara M; Okamoto K; Kadowaki T; Kusano K; Fukamizu A; Yoshimura T
    Drug Metab Dispos; 2010 Mar; 38(3):526-33. PubMed ID: 20007293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
    Shi Y; Zhang J; Liu M; Huang Y; Yin L
    J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner.
    Wanderley CW; Colón DF; Luiz JPM; Oliveira FF; Viacava PR; Leite CA; Pereira JA; Silva CM; Silva CR; Silva RL; Speck-Hernandez CA; Mota JM; Alves-Filho JC; Lima-Junior RC; Cunha TM; Cunha FQ
    Cancer Res; 2018 Oct; 78(20):5891-5900. PubMed ID: 30104241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel-exposed ovarian cancer cells induce cancer‑specific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression.
    Kim JE; Jang MJ; Jin DH; Chung YH; Choi BS; Park GB; Kim YS; Kim S; Hur DY; Hung CF; Kim D
    Int J Oncol; 2014 May; 44(5):1716-26. PubMed ID: 24573741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
    Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
    Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.